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Objective: The aim was to update the guidelines for the management of thyroid dysfunction
during pregnancy and postpartum published previously in 2007. A summary of changes between
the 2007 and 2012 version is identified in the Supplemental Data (published on The Endocrine
Society’s Journals Online web site at http://jcem.endojournals.org).
Evidence:Thisevidence-basedguidelinewasdevelopedaccordingtotheU.S.PreventiveServiceTaskForce,
grading items level A, B, C, D, or I, on the basis of the strength of evidence andmagnitude of net benefit
(benefitsminus harms) aswell as theGrading of Recommendations, Assessment, Development, and Eval-
uation (GRADE) system to describe both the strength of recommendations and the quality of evidence.
Consensus Process: The guideline was developed through a series of e-mails, conference calls, and one
face-to-facemeeting.AninitialdraftwaspreparedbytheTaskForce,withthehelpofamedicalwriter,and
reviewedandcommentedonbymembersofTheEndocrineSociety,AsiaandOceaniaThyroidAssociation,
and the Latin American Thyroid Society. A second draft was reviewed and approved by The Endocrine
Society Council. At each stage of review, the Task Force received written comments and incorporated
substantive changes.
Conclusions:Practiceguidelinesarepresentedfordiagnosisandtreatmentofpatientswiththyroid-related
medical issues just before and during pregnancy and in the postpartum interval. These include evidence-
based approaches to assessing the cause of the condition, treating it, and managing hypothyroidism,
hyperthyroidism, gestational hyperthyroidism, thyroid autoimmunity, thyroid tumors, iodine nutrition,
postpartumthyroiditis,andscreeningforthyroiddisease. Indicationsandsideeffectsoftherapeuticagents
used in treatment are also presented. (J Clin Endocrinol Metab 97: 2543–2565, 2012)
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This revised guideline replaces the previous version published in 2007: AbalovichM,Amino
N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A. Man-
agement of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society
Clinical Practice Guideline. J Clin Endocrinol Metab 2007 Aug;92(8 Suppl):S1–S47.
This guideline is also available with CME. Go to http://www.endo-society.org/guidelines/
Current-Clinical-Practice-Guidelines.cfm for more details.
Abbreviations: ATD, Antithyroid drug; DM, diabetes mellitus; FNA, fine-needle aspiration; GH,
gestationalhyperthyroidism;hCG,humanchorionicgonadotropin;MMI,methimazole;PPD,post-
partumdepression; PPT, postpartum thyroiditis; PTU, propylthiouracil; RAI, radioactive iodine; RNI,
recommendednutrient intake;SCH, subclinicalhypothyroidism;TG, thyroglobulin; TPO-Ab, thy-
roidperoxidaseantibodynegative;TPO-Ab,TPO-Abpositive;TRAb,TSHreceptorantibodies;UIC,
urinary iodine concentration; UIE, urinary iodine excretion; USI, universal salt iodization.
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Summary of Recommendations
1.0. Management of hypothyroidism: maternal
and fetal aspects
1.1. We recommend caution in the interpretation of
serum free T4 levels during pregnancy and that each lab-
oratory establish trimester-specific reference ranges for
pregnantwomen if using a free T4 assay. The nonpregnant
total T4 range (5–12 g/dl or 50–150 nmol/liter) can be
adapted in the second and third trimesters by multiplying
this range by 1.5-fold. Alternatively, the free T4 index
(“adjusted T4”) appears to be a reliable assay during preg-
nancy. U.S. Preventive Service Task Force (USPSTF) rec-
ommendation level: B; evidence, fair (GRADE 2QQEE).
1.2.1. Overt maternal hypothyroidism is known to
have serious adverse effects on the fetus. Therefore, ma-
ternal hypothyroidism should be avoided. For overt hy-
pothyroidism: USPSTF recommendation level: A; evi-
dence, good (1QQQE).
1.2.2. Subclinical hypothyroidism (SCH; serum TSH
concentration above the upper limit of the trimester-spe-
cific reference range with a normal free T4) may be asso-
ciated with an adverse outcome for both the mother and
offspring, as documented in antibody-positive women. In
retrospective studies, T4 treatment improved obstetrical
outcome, but it has not been proved to modify long-term
neurological development in the offspring. However,
given that the potential benefits outweigh the potential
risks, the panel recommends T4 replacement in women
with SCH who are thyroid peroxidase antibody positive
(TPO-Ab). For obstetrical outcome: USPSTF recom-
mendation level, B; evidence, fair (2QQEE); for neuro-
logical outcome, USPSTF recommendation level, I; evi-
dence, poor (2EEEE). The panel also recommends T4
replacement in women with SCH who are TPO-Ab neg-
ative (TPO-Ab). For obstetrical outcome: USPSTF rec-
ommendation level, C; evidence, fair (2QQEE); for neu-
rological outcome: USPSTF recommendation level, I;
evidence, poor (2EEEE).
1.2.3. If hypothyroidism has been diagnosed before
pregnancy, we recommend adjustment of the preconcep-
tion T4 dose to reach before pregnancy a TSH level not
higher than 2.5mIU/liter. USPSTF recommendation level:
C; evidence, poor (2QEEE).
1.2.4. The T4 dose usually needs to be incremented by
4 to 6 wk gestation and may require a 30% or more in-
crease in dosage. USPSTF recommendation level: A; evi-
dence, good (1QQQQ).
1.2.5. If overt hypothyroidism is diagnosed during
pregnancy, thyroid function tests should be normalized as
rapidly as possible. T4 dosage should be titrated to rapidly
reach and thereafter maintain serum TSH concentrations
of less than 2.5 mIU/liter (in an assay using the Interna-
tional Standard) in the first trimester (or 3 mIU/liter in
second and third trimesters) or to trimester-specific TSH
ranges. Thyroid function tests should be remeasured
within 30–40 d and then every 4–6 wk. USPSTF recom-
mendation level: A; evidence, good (1QQQQ).
1.2.6.Women with thyroid autoimmunity who are eu-
thyroid in the early stages of pregnancy are at risk of de-
veloping hypothyroidism and should be monitored every
4–6 wk for elevation of TSH above the normal range for
pregnancy. USPSTF recommendation level: A; evidence,
fair (1QQQE).
1.2.7. After delivery,most hypothyroidwomen need to
decrease the T4 dosage they received during pregnancy to
the prepregnancydose.USPSTF recommendation level:A;
evidence, good (1QQQQ).
2.0. Management of hyperthyroidism: maternal
and fetal aspects
2.1. Management of maternal hyperthyroidism: ma-
ternal aspects
2.1.1. If a subnormal serum TSH concentration is
detected during gestation, hyperthyroidismmust be dis-
tinguished from both normal physiology of pregnancy
and gestational thyrotoxicosis because of the adverse
effects of overt hyperthyroidism on the mother and fe-
tus. Differentiation of Graves’ disease from gestational
thyrotoxicosis is supported by the presence of clinical
evidence of autoimmunity, a typical goiter, and pres-
ence of TSH receptor antibodies (TRAb). TPO-Ab may
be present in either case. USPSTF recommendation lev-
el: B; evidence, fair (1QQQE).
2.1.2. Forovert hyperthyroidismdue toGraves’ disease
or thyroid nodules, antithyroid drug (ATD) therapy
should be either initiated (before pregnancy if possible,
and for those with new diagnoses) or adjusted (for those
with a prior history) to maintain the maternal thyroid
hormone levels for free T4 at or just above the upper limit
of the nonpregnant reference range, USPSTF recommen-
dation level: B; evidence, fair (1QQEE), or to maintain
totalT4 at 1.5 times theupper limit of the normal reference
range or the free T4 index in the upper limit of the normal
reference range. USPSTF recommendation level: I; evi-
dence, poor (2QEEE).
2.1.3. Propylthiouracil (PTU), if available, is recom-
mended as the first-line drug for treatment of hyperthy-
roidism during the first trimester of pregnancy because of
the possible association of methimazole (MMI) with spe-
cific congenital abnormalities that occur during first tri-
mester organogenesis.MMImayalso be prescribed if PTU
is not available or if a patient cannot tolerate or has an
adverse response to PTU. MMI 10 mg is considered to be
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approximately equal to 100–150mgof PTU.Recent anal-
yses reported by the U.S. Food and Drug Administration
(FDA) indicate that PTU may rarely be associated with
severe liver toxicity. For this reason we recommend that
clinicians change treatment of patients from PTU toMMI
after the completion of the first trimester. Available data
indicate that MMI and PTU are equally efficacious in the
treatment of pregnant women. Practitioners should use
their clinical judgment in choosing the ATD therapy,
including the potential difficulties involved in switching
patients from one drug to another. If switching from
PTU to MMI, thyroid function should be assessed after
2 wk and then at 2- to 4-wk intervals. USPSTF recom-
mendation level: B; evidence, fair (1QQEE). Although
liver toxicity may appear abruptly, it is reasonable to
monitor liver function in pregnantwomen on PTU every
3–4 wk and to encourage patients to promptly report
any new symptoms. USPSTF recommendation level: C;
evidence, poor (2QEEE).
2.1.4. Subtotal thyroidectomymay be indicated during
pregnancy as therapy for maternal Graves’ disease if: 1) a
patient has a severe adverse reaction to ATD therapy; 2)
persistently high doses of ATD are required (over 30mg/d
of MMI or 450 mg/d of PTU); or 3) a patient is nonad-
herent to ATD therapy and has uncontrolled hyperthy-
roidism. The optimal timing of surgery is in the second
trimester. USPSTF recommendation level: C; evidence,
fair (2QEEE).
2.1.5. There is no evidence that treatment of subclin-
ical hyperthyroidism improves pregnancy outcome, and
treatment could potentially adversely affect fetal out-
come. USPSTF recommendation level: C; evidence, fair
(2QEEE).
2.2.Management ofmaternal hyperthyroidism: fetal
aspects
2.2.1.Because thyroid receptorantibodies (thyroid recep-
tor stimulating,binding,or inhibitingantibodies) freelycross
the placenta and can stimulate the fetal thyroid, these anti-
bodies shouldbemeasuredby22wkgestationalage inmoth-
erswith: 1) currentGraves’ disease; or2) ahistoryofGraves’
disease and treatment with 131I or thyroidectomy before
pregnancy; or 3) a previous neonatewithGraves’ disease; or
4) previously elevated TRAb. Women who have a negative
TRAb and do not require ATD have a very low risk of fetal
or neonatal thyroid dysfunction. USPSTF recommendation
level: B; evidence, fair (1QQQE).
2.2.2. 131I should not be given to a woman who is or
may be pregnant. If inadvertently treated, the patient
should be promptly informed of the radiation danger to
the fetus, including thyroid destruction if treated after the
12thweekof gestation.USPSTF recommendation level:A;
evidence, good (1QQQE).There arenodata foror against
recommending termination of pregnancy after 131I expo-
sure. USPSTF recommendation level: I; evidence, poor
(2QEEE).
2.2.3. In women with TRAb or thyroid-stimulating Ig
elevated at least 2- to3-fold thenormal level and inwomen
treated with ATD, maternal free T4 and fetal thyroid dys-
function should be screened for during the fetal anatomy
ultrasound done in the 18th-22nd week and repeated ev-
ery 4–6 wk or as clinically indicated. Evidence of fetal
thyroid dysfunction could include thyroid enlargement,
growth restriction, hydrops, presence of goiter, ad-
vanced bone age, tachycardia, or cardiac failure. If fetal
hyperthyroidism is diagnosed and thought to endanger
the pregnancy, treatment using MMI or PTU should be
given with frequent clinical, laboratory, and ultrasound
monitoring. USPSTF recommendation level: B; evi-
dence, fair (1QQQE).
2.2.4. Umbilical blood sampling should be considered
only if the diagnosis of fetal thyroid disease is not reason-
ably certain fromthe clinical and sonographicdata and the
information gained would change the treatment. USPSTF
recommendation level: B; evidence, fair (2QEEE).
2.2.5. All newborns of mothers with Graves’ disease
(except thosewith negativeTRAbandnot requiringATD)
should be evaluated by amedical care provider for thyroid
dysfunction and treated if necessary. USPSTF recommen-
dation level: B; evidence, fair (1QQQE).
3.0. Gestational hyperemesis and hyperthyroidism
3.1. Thyroid function tests (TSH, total T4, or free T4
index, or free T4) and TRAb should be measured in pa-
tients with hyperemesis gravidarum (5% weight loss, de-
hydration, and ketonuria) and clinical features of hyper-
thyroidism. USPSTF recommendation level: B; evidence,
fair (2QQEE).
3.2. Most women with hyperemesis gravidarum, clin-
ical hyperthyroidism, suppressed TSH, and elevated free
T4 do not require ATD treatment. USPSTF recommenda-
tion level:A; evidence, good (1QQQQ). Clinical judgment
should be followed in women who appear significantly
thyrotoxic or who have in addition serum total T3 values
above the reference range for pregnancy. Beta blockers
such as metoprolol may be helpful and may be used with
obstetrical agreement. USPSTF recommendation level: B;
evidence, poor (2QEEE).
3.3.Womenwithhyperemesisgravidarumanddiagnosed
tohaveGraves’hyperthyroidism(freeT4above the reference
range or total T4  150% of top normal pregnancy value,
TSH  0.01 IU/liter, and presence of TRAb) will require
ATD treatment, as clinically necessary. USPSTF recommen-
dation level: A; evidence, good (1QQQQ).
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4.0. Autoimmune thyroid disease and miscarriage
4.1. A positive association exists between the presence
of thyroid antibodies and pregnancy loss. Universal
screening for antithyroid antibodies, and possible treat-
ment, cannot be recommended at this time. As of January
2011, only one randomized interventional trial has sug-
gested a decrease in the first trimester miscarriage rate in
euthyroid antibody-positive women, but treatment dura-
tion was very brief before the outcome of interest. How-
ever, because women with elevated anti-TPO antibodies
are at increased risk for progression of hypothyroidism, if
identified such women should be screened for serum TSH
abnormalities before pregnancy, as well as during the first
and second trimesters of pregnancy. USPSTF recommen-
dation level: C; evidence, fair (2QEEE).
5.0. Thyroid nodules and cancer
5.1. Fine-needle aspiration (FNA) cytology should be
performed for predominantly solid thyroid nodules larger
than 1 cm discovered in pregnancy. Women with nodules
5 mm to 1 cm in size should be considered for FNA if they
have a high-risk history or suspicious findings on ultra-
sound, and women with complex nodules 1.5 to 2 cm or
larger should also receive an FNA. During the last weeks
of pregnancy, FNA can reasonably be delayed until after
delivery. Ultrasound-guided FNA is likely to have an ad-
vantage for maximizing adequate sampling. USPSTF rec-
ommendation level: B; evidence, fair (1QQQE).
5.2. When nodules discovered in the first or early sec-
ond trimester are found to be malignant or highly suspi-
cious on cytopathological analysis, to exhibit rapid
growth, or to be accompanied by pathological neck ade-
nopathy, pregnancy need not be interrupted, but surgery
should be offered in the second trimester. Women found
tohave cytology indicative of papillary cancer or follicular
neoplasm without evidence of advanced disease and who
prefer to wait until the postpartum period for definitive
surgery may be reassured that most well-differentiated
thyroid cancers are slow growing and that delaying sur-
gical treatment until soon after delivery is unlikely to
change disease-specific survival. USPSTF recommenda-
tion level: B; evidence, fair (1QQEE).
5.3. It is appropriate to administer thyroid hormone to
achieve a suppressed but detectable TSH in pregnant
women with a previously treated thyroid cancer, in those
with an FNA positive for or suspicious for cancer, or in
those who elect to delay surgical treatment until postpar-
tum. High-risk patients may benefit more than low-risk
patients from a greater degree of TSH suppression. The
free T4 or total T4 levels should ideally not be increased
above the normal range for pregnancy. USPSTF recom-
mendation level: I; evidence, poor (2QEEE).
5.4. Radioactive iodine (RAI) with 131I should not be
given to womenwho are breastfeeding or for at least 4 wk
after nursing has ceased. USPSTF recommendation level:
A; evidence, good (1QQQQ). Furthermore, pregnancy
should be avoided for 6 months to 1 yr in women with
thyroid cancer who receive therapeutic RAI doses to en-
sure stability of thyroid function and confirm remission of
thyroid cancer. USPSTF recommendation level: B; evi-
dence, fair (1QQEE).
6.0. Iodine nutrition during pregnancy
6.1. Women in the childbearing age should have an
average iodine intake of 150 g/d. As long as possible
before pregnancy and during pregnancy and breastfeed-
ing, women should increase their daily iodine intake to
250 g on average. USPSTF recommendation level: A;
evidence, good (1QQQE).
6.2. Iodine intake during pregnancy and breastfeeding
should not exceed twice the daily recommended nutrient in-
take (RNI) for iodine, i.e. 500 g iodine per day. USPSTF
recommendation level: I; evidence, poor (2QEEE).
6.3. Although not advised as a part of normal clinical
practice, the adequacy of the iodine intake during preg-
nancy can be assessed by measuring urinary iodine con-
centration (UIC) in a representative cohort of the popu-
lation. UIC should ideally range between 150 and 250
g/liter. If there is significant concern, the caregiver should
assay TSH and thyroid hormone levels. USPSTF recom-
mendation level: A; evidence, good (1QQQQ).
6.4. To reach the daily recommended nutrient intake
for iodine, multiple means must be considered, tailored to
the iodine intake level in a given population. Different
situations must therefore be distinguished: 1) countries
with iodine sufficiency and/or with awell-established uni-
versal salt iodization (USI) program; 2) countries without
a USI program or with an established USI program where
the coverage is known to be only partial; and 3) remote
areas with no accessible USI program and difficult socio-
economic conditions. USPSTF recommendation level: A;
evidence, good (1QQQQ).
6.5. We recommend that once-daily prenatal vitamins
contain 150–200 g iodine and that this be in the form of
potassiumiodideor iodate, the contentofwhich is verified to
ensure that all pregnantwomen taking prenatal vitamins are
protected from iodine deficiency. Ideally, supplementation
shouldbestartedbeforeconception.Preparationscontaining
ironsupplements shouldbeseparatedfromthyroidhormone
administrationby at least 4h.USPSTF recommendation lev-
el: B; evidence, fair (2QQEE).
6.6. We recommend that breastfeeding women main-
tain a daily intake of 250g of iodine to ensure that breast
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milk provides 100g iodine per day to the infant. USPSTF
recommendation level: A; evidence, good (1QQQE).
7.0. Postpartum thyroiditis
7.1.There are insufficientdata to recommendscreening
of all women for postpartum thyroiditis (PPT). USPSTF
recommendation level: I; evidence, poor (2QEEE).
7.2. Women known to be TPO-Ab should have TSH
measured at 6–12 wk gestation and at 6 months postpar-
tum, or as clinically indicated. USPSTF recommendation
level: A; evidence, good (1QQQE).
7.3. Because the prevalence of PPT inwomenwith type
1 diabetes, Graves’ disease in remission, and chronic viral
hepatitis is greater than in the general population, screen-
ing by TSH is recommended at 3 and 6 months postpar-
tum. USPSTF recommendation level: B; evidence, fair
(2QQEE).
7.4. Women with a history of PPT have a markedly
increased risk of developing permanent primary hypo-
thyroidism in the 5- to 10-yr period after the episode of
PPT. An annual TSH level should be performed in these
women. USPSTF recommendation level: A; evidence,
good (1QQQE).
7.5. Asymptomatic women with PPT who have a TSH
above the reference range but less than 10 mIU/liter and
who are not planning a subsequent pregnancy do not nec-
essarily require intervention but should, if untreated, be
remonitored in 4–8 wk.When a TSH above the reference
range continues, women should be treated with levothy-
roxine. Symptomatic women and women with a TSH
above normal and who are attempting pregnancy should
be treated with levothyroxine. USPSTF recommendation
level: B; evidence, fair (2QQEE).
7.6. There is insufficient evidence to conclude whether
an association exists between postpartum depression
(PPD) and either PPT or thyroid antibody positivity (in
women who did not develop PPT). USPSTF recommen-
dation level: I; evidence, poor (2QEEE). However, be-
cause hypothyroidism is a potentially reversible cause of
depression, women with PPD should be screened for hy-
pothyroidism and appropriately treated. USPSTF recom-
mendation level: B; evidence, fair (2QQEE).
8.0. Screening for thyroid dysfunction during
pregnancy
8.1a. Universal screening of healthy women for thyroid
dysfunctionbeforepregnancy is not recommended.USPSTF
recommendation level: I; evidence, poor (2QEEE).
8.1b. However, caregivers should identify individuals
at “high risk” for thyroid illness (see Table 1) on the basis
of their medical history, physical exam, or prior biochem-
icaldata.Whensuchindividualsare identified,prenatalmea-
surement of serum TSH is recommended. If it is above 2.5
mIU/liter, the test should be confirmed by repeat assay. Al-
thoughnorandomizedcontrolledtrialsareavailable toguide
a response, the committee believes it is appropriate to give
low-dose T4 treatment to bring TSH below 2.5 mIU/liter.
This treatment can be discontinued if the woman does not
become pregnant or postpartum. USPSTF recommendation
level: I; evidence, poor (2QEEE).
8.2a. All women considering pregnancy with known
thyroid dysfunction and receiving levothyroxine should
be tested for abnormal TSH concentrations before preg-
nancy. USPSTF recommendation level: B; evidence, fair
(1QQEE).
8.2b. If hypothyroidism has been diagnosed before
pregnancy, we recommend adjustment of the preconcep-
tion T4 dose to reach before pregnancy a TSH level not
higher than 2.5mIU/liter. USPSTF recommendation level:
C; evidence, fair (2QQEE).
8.2c. All women receiving levothyroxine should be ver-
bally screened prenatally to assess their understanding of
changing levothyroxine requirements after conception.
These women should be counseled to contact a physician
or medical professional immediately upon a missed men-
strual cycle or suspicion of pregnancy to check their serum
TSH level. An additional recommendation may be to in-
crease their levothyroxine dose by 30%, which is often
two additional tablets per week (nine tablets per week
instead of seven tablets), until their serum TSH can be
checked. USPSTF recommendation level: B; evidence, fair
(2QQEE).
8.3a. Universal screening for the presence of anti-TPO
antibodies either before or during pregnancy is not rec-
ommended. USPSTF recommendation level: C; evidence,
fair (2QEEE).
8.3b. However, women with elevated anti-TPO an-
tibodies are at increased risk for miscarriage, preterm
delivery, progression of hypothyroidism, and PPT.
Therefore, if identified, such women should be screened
for serum TSH abnormalities before pregnancy, as well
as during the first and second trimesters of pregnancy.
USPSTF recommendation level: C; evidence, fair
(1QQEE) (see also Section 8.5).
8.4a. The committee could not reach agreement with
regard to screening recommendations for all newly preg-
nant women. Two versions are therefore presented.
8.4a1. Some members recommended screening of all
pregnant women for serum TSH abnormalities by the
ninth week or at the time of their first visit. USPSTF rec-
ommendation level: C; evidence, fair (2QQEE) (Authors
supporting: L.D.G., J.R., J.H.L., N.A., C.J.E.).
8.4a2. Some members recommended neither for nor
against universal screeningof all pregnantwomen forTSH
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abnormalities at the timeof their first visit. Thesemembers
strongly support aggressive case finding to identify and
test high-risk women (Table 1) for elevated TSH concen-
trations by the ninth week or at the time of their first visit
before and during pregnancy, and they recognize that in
some situations ascertainment of the individual’s risk sta-
tus may not be feasible. In such cases, and where the local
practice environment is appropriate, testing of all women
by wk 9 of pregnancy or at the first prenatal visit is rea-
sonable. USPSTF recommendation level: I; evidence, poor
(2QEEE) (Authors supporting:M.A., E.K.A., J.M., L.B.,
S.S., S.J.M., D.L., R.H.C.).
8.4b. If serumTSH is greater than 2.5mIU/liter at the
time of testing (or 3.0 mIU/liter in the second trimes-
ter), levothyroxine therapy should be instituted. For
overt hypothyroidism, USPSTF recommendation level:
A; evidence, good (1QQQQ); for SCH and obstetrical
outcome, USPSTF recommendation level: C; evidence,
fair (2QQEE); and for SCH and neurological outcome,
USPSTF recommendation level: C; evidence, poor
(2QEEE).
8.4c. If TSH concentration is 2.5–10 mIU/liter, a start-
ing levothyroxine dose of 50 g/d or more is recom-
mended. Other thyroid preparations (such as T3) are not
recommended. USPSTF recommendation level: C; evi-
dence, fair (2QQEE).
8.5. Women at high risk for PPT in the postpartum
months should be screened via assessment of serum TSH.
These high-risk groups include: 1) women known to be
TPO-Ab; 2) womenwith type 1 diabetes; and 3) women
with a prior history of PPT. Screening should occur at
6–12 wk postpartum. Women with Graves’ disease who
enter remission during pregnancy should be screened for
recurrence by TSH assay at 3–6 months. USPSTF recom-
mendation level: C; evidence, poor (2QEEE) (see also
Section 7).
Method of Development of Evidence-
Based Clinical Practice Guidelines
The Clinical Guidelines Subcommittee of The Endocrine
Society deemed thyroid dysfunction during pregnancy a
priority area in need of practice guidelines and appointed
a task force to formulate evidence-based recommenda-
tions. The task force followed the approach of the U.S.
Preventive Service Task Force and the Grading of Recom-
mendations, Assessment, Development, and Evaluation
(GRADE) system to evaluate the strength of each recom-
mendation and the quality of the evidence. The task force
used the best available research evidence to develop the
recommendations. In the USPSTF system, the strength of
a recommendation is graded A, B, C, D, or I (if insuffi-
cient), and evidence is graded good, fair, or poor. In the
GRADE system strong recommendations use the number
1, and weak recommendations use the number 2. Cross-
filled circles indicate the quality of the evidence, such that
QEEE denotes very low quality evidence; QQEE, low
quality;QQQE, moderate quality; andQQQQ, high qual-
ity. The task force has confidence that personswho receive
care according to the strong recommendationswill derive,
on average, more good than harm. Weak recommenda-
tions require more careful consideration of the person’s
circumstances, values, and preferences to determine the
best course of action. Linked to each recommendation
is a description of the evidence and the values that pan-
elists considered in making the recommendation; in
some instances, there are remarks, a section in which
panelists offer technical suggestions for testing condi-
tions, dosing, and monitoring. These technical com-
ments reflect the best available evidence applied to a
typical person being treated.
This guideline is concerned with the management of
pregnant women who may have a variety of known or
undisclosed thyroid conditions, such as hypothyroidism
and hyperthyroidism, the presence of thyroid autoanti-
bodies, the presence of nodules, or inadequate iodine nu-
trition. Pregnancy may affect the course of these thyroid
disorders, and conversely, thyroid diseases may affect the
course of pregnancy. Moreover, the thyroid disorders
(and their management) may affect both the pregnant
woman and the developing fetus. Finally, pregnant
womenmay be under the care of multiple health care pro-
fessionals, including obstetricians, nursemidwives, family
practitioners, endocrinologists, and/or internists, making
the development of guidelines all the more critical.
An international task force was created under the aus-
pices of The Endocrine Society to review the best evidence
in the field and develop evidence-based guidelines, and a
reportwas issued in2007.Because of advances in the field,
the committee was reconvened in 2009. The current task
force also includesmembers of the Asia andOceania Thy-
roid Association and the Latin American Thyroid Society.
The task force undertook a review of all material on
these topics published in English during the past two de-
cades, or earlier at the working group’s discretion. We
concentrated on original reports and largely excluded re-
views from our references. At present, with the exception
of studies on iodide nutrition, only a few prospective, ran-
domized intervention trials have been published in this
area.We are aware of large-scale prospective intervention
trials that are ongoing. Nevertheless, in the past decade
many high-quality studies have modified older dogmas
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and profoundly changed the ways in which these patients
are managed.
Thyroidproblemsduringpregnancy encompass at least
eight different conditions, and we have therefore divided
our report into the following sections:
1. Management of hypothyroidism: maternal and fetal
aspects
2. Managementofhyperthyroidism:maternal and fetal
aspects
3. Gestational hyperemesis and hyperthyroidism
4. Autoimmune thyroid disease and miscarriage
5. Thyroid nodules and cancer
6. Iodine nutrition during pregnancy
7. Postpartum thyroiditis
8. Screening for thyroid dysfunction during pregnancy
The material herein is a condensed and abstracted ver-
sion of the full report, which is published online at http://
www.endo-society.org/guidelines/Current-Clinical-Practice-
Guidelines.cfm. Each subsection provides recommendations
followedbyanabbreviated examinationof evidence.Each rec-
ommendation is followedby a statement of strengthof the rec-
ommendation and quality of the evidence. We have indicated
the specific bibliographic citations on which each recommen-
dation is based.
1.0. Management of hypothyroidism during
pregnancy: maternal and fetal aspects
Recommendations
1.1. We recommend caution in the interpretation of
serum free T4 levels during pregnancy and that each lab-
oratory establish trimester-specific reference ranges for
pregnantwomen if using a free T4 assay. The nonpregnant
total T4 range (5–12 g/dl or 50–150 nmol/liter) can be
adapted in the second and third trimesters by multiplying
this range by 1.5-fold. Alternatively, the free T4 index
(“adjusted T4”) appears to be a reliable assay during preg-
nancy. USPSTF recommendation level: B; evidence, fair
(GRADE 2QQEE) (1–3).
1.2.1. Overt maternal hypothyroidism is known to
have serious adverse effects on the fetus (4–8). Therefore
maternal hypothyroidism should be avoided. For overt
hypothyroidism: USPSTF recommendation level: A; evi-
dence, good (1QQQE).
1.2.2. SCH (serumTSH concentration above the upper
limit of the trimester-specific reference range with a nor-
mal free T4) may be associated with an adverse outcome
forboth themother andoffspring. In retrospective studies,
and in prospective studies onwomenwith SCH and TPO-
Ab, T4 treatment improved obstetrical outcome, but it
has not been proved to modify long-term neurological
development in the offspring. However, given that the
potential benefits outweigh the potential risks, the panel
recommends T4 replacement in women with SCH. For
obstetrical outcome: USPSTF recommendation level, C;
evidence, fair (2QQEE) (4–9); for neurological outcome:
USPSTF recommendation level, I; evidence, poor
(2EEEE) (4–7, 9).
1.2.3. If hypothyroidism has been diagnosed before
pregnancy, we recommend adjustment of the preconcep-
tion T4 dose to reach before pregnancy a TSH level not
higher than 2.5mIU/liter. USPSTF recommendation level:
C; evidence, poor (2QEEE) (1, 10–12).
1.2.4. The T4 dose usually needs to be incremented by
4 to 6 wk gestation and may require a 30% or more in-
crease in dosage. USPSTF recommendation level: A; evi-
dence, good (1QQQQ) (12–15).
1.2.5. If overt hypothyroidism is diagnosed during
pregnancy, thyroid function tests should be normalized
as rapidly as possible. T4 dosage should be titrated to
rapidly reach and thereafter maintain serum TSH con-
centrations of less than 2.5 mIU/liter (in an assay using
the International Standard) in the first trimester (or 3
mIU/liter in second and third trimesters) or to trimester-
specific TSH ranges. Thyroid function tests should be
remeasured within 30–40 d and then every 4–6 wk.
USPSTF recommendation level: A; evidence, good
(1QQQQ) (3, 11, 16, 17).
1.2.6.Women with thyroid autoimmunity who are eu-
thyroid in the early stages of pregnancy are at risk of de-
veloping hypothyroidism and should be monitored for el-
evation of TSH above the normal range for pregnancy
every 4–6 wk. USPSTF recommendation level: A; evi-
dence, fair (1QQQE) (12, 14).
1.2.7. After delivery,most hypothyroidwomen need to
decrease the T4 dosage they received during pregnancy to
the prepregnancydose.USPSTF recommendation level:A;
evidence, good (1QQQQ) (18).
1.1.–1.2.7. Background and evidence
Overt hypothyroidismoccurs in 0.3–0.5%of pregnan-
cies, and SCH occurs in 2–3%. Thyroid autoantibodies
are found in 5–15% of women during childbearing age,
and chronic autoimmune thyroiditis is the main cause of
hypothyroidism, apart from iodine deficiency (19). Other
causes include radioiodine ablation or surgery for hyper-
thyroidism, thyroid tumor surgery, congenital hypothy-
roidism, and rarely, lymphocytic hypophysitis.
Hypothyroid women are more likely to experience in-
fertility, and they have an increased prevalence of abor-
tion, anemia, gestational hypertension, placental abrup-
tion, and postpartum hemorrhage (4–9). Untreated
maternal overt hypothyroidism is associated with adverse
neonatal outcomes including premature birth, low birth
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weight, and neonatal respiratory distress. There may be
more fetal and perinatal death, and gestational hyperten-
sionmayalso contribute to theoverall increase inneonatal
risks. Women with gestational SCH were found in one
study to have more preterm deliveries (20), and the off-
spring have more admissions to neonatal intensive care
and an increased rate of respiratory distress syndrome (4).
Even maternal TSH levels in the upper normal range are
associated with increased fetal loss, as compared with
lower “normal” levels (11).
Thyroid hormone contributes critically to normal fetal
brain development (21). In moderate and severe iodine
deficiency, there is significant childhood IQ reduction,
preventable by gestational iodine supplementation. In io-
dine-sufficient areas, there is also a significantly increased
risk of impairment in neuropsychological developmental
indices, IQ scores, and school learning abilities in the off-
spring of hypothyroid mothers. A study in the United
States showed that children born to untreated hypothy-
roid women had an IQ score seven points below the mean
IQ of children born to healthy women (6). Children born
to untreated hypothyroid mothers were three times more
likely tohave IQ thatwere1 SDbelow themeanof controls.
Early maternal low free T4 has been associated with a
lower developmental index in children at 10 months of
age, and children born to mothers with prolonged low T4
(until wk 24 or later) showed an 8- to 10-point deficit for
motor and mental development (22). If free T4 recovered
spontaneously to normal later in gestation, infants had a
normal development, suggesting that prolonged low T4
was needed to impair fetal neural development. A recent
study byHenrichs et al. (23) confirmed the adverse effects
of maternal free T4 levels in the lowest 10% of the normal
range on early childhood cognitive development.
Diagnosis.Hypothyroidismmaybe suggestedby cold sen-
sitivity, fatigue, or dry skin or it may go unnoticed. Be-
cause many women remain asymptomatic, particular at-
tention is required from obstetrical care providers for
careful diagnosis and, if appropriate, thyroid function
evaluation at the first prenatal clinic attendance.Only thy-
roid function tests confirm the diagnosis.
Total serumT4 rises rapidly during the first trimester to
roughly 150% of the nonpregnant range because of es-
trogen-induced elevation of T4 binding globulin. Serum
TSHelevation suggests primary hypothyroidism. Thyroid
autoantibody titers [TPO-Ab or thyroglobulin (TG) anti-
bodies] confirm an autoimmune origin (12). Serum TSH
values are normally lowered, particularly near the end of
the first trimester, because of the thyrotropic activity of
elevated circulating human chorionic gonadotropin
(hCG) concentrations. In the first trimester, the “normal”
range is reduced to 0.1–2.5 mIU/liter (2, 24). Thus, a se-
rum TSH within the classical reference range (0.4–4.0
mIU/liter) might be misdiagnosed as “normal” in women
who have a slight TSH elevation, or hyperthyroidismmay
be wrongly suspected in normal women who have a
blunted serum TSH.
Serum T4 distinguishes between SCH and overt hypo-
thyroidism, if normal, or clearly below normal for gesta-
tional age, respectively. Reference ranges provided by the
manufacturersofmost freeT4measurementkits havebeen
established using pools of nonpregnant normal sera, and
such reference ranges are not valid during pregnancy. If
free T4 is the only test available, pregnancy-specific refer-
ence ranges should be established for each assay. The non-
pregnant total T4 range (5–12g/dl or 50–150nmol/liter)
can be adapted in the second and third trimesters by mul-
tiplying this range by 1.5-fold. Alternatively, the free T4
index (“adjustedT4”) appears to be a reliable assay during
pregnancy.
Treatment. Levothyroxine is the treatment of choice for
maternal hypothyroidism, assuming adequate iodine nu-
trition (14). Hypothyroid pregnant women require larger
levothyroxine doses than do nonpregnant patients.
Women receiving T4 antenatally usually should increase
their dosage by 4–6 wk gestation to 30–50% above pre-
conception dosage (14, 15). The increment is greater in
women without residual functional thyroid tissue (e.g. ra-
dioiodine ablation, total thyroidectomy) than in those with
residual thyroid tissue (e.g. Hashimoto’s thyroiditis) (15).
When serum TSH is first checked during pregnancy, the av-
erage incrementsof levothyroxineneededare25–50g/d for
serum TSH levels between 5 and 10 mIU/liter, 50–75 g/d
for serum TSH between 10 and 20 mIU/liter, and 75–100
g/d for those with a serum TSH above 20 mIU/liter.
Management of a pregnant woman with normal TSH
for pregnancy, but with thyroid hormone level by reliable
assay below the pregnancy and trimester normal range on
repeat assay, is controversial and requires further study
(22, 23).However, in theopinionof the committee, partial
replacement therapy may be initiated at the discretion of
the caregiver, with continued monitoring.
2.0. Management of hyperthyroidism: maternal
and fetal aspects
Recommendations
2.1. Management of maternal hyperthyroidism:
maternal aspects
2.1.1. If a subnormal serum TSH concentration is
detected during gestation, hyperthyroidismmust be dis-
tinguished from both normal physiology of pregnancy
2550 De Groot et al. Summary: Guidelines for Thyroid Dysfunction in Pregnancy J Clin Endocrinol Metab, August 2012, 97(8):2543–2565
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/97/8/2543/2823170 by U
niversity of R
hode Island Library user on 16 M
ay 2019
and gestational thyrotoxicosis because of the adverse
effects of overt hyperthyroidism on the mother and fe-
tus. Differentiation of Graves’ disease from gestational
thyrotoxicosis is supported by the presence of clinical
evidence of autoimmune thyroid disease, a typical goi-
ter, and the presence of TRAb. TPO-Ab may be present
in either case. USPSTF recommendation level: B; evi-
dence, fair (1QQQE) (24–26).
2.1.2.ForoverthyperthyroidismduetoGraves’diseaseor
thyroid nodules, ATD therapy should be either initiated (be-
forepregnancy if possible, and for thosewithnewdiagnoses)
or adjusted (for those with a prior history) to maintain the
maternal thyroidhormone levels for freeT4at theupper limit
of the nonpregnant reference range. USPSTF recommenda-
tion level:B; evidence, fair (1QQEE); or tomaintain totalT4
at 1.5 times the upper limit of the normal reference range, or
the free T4 index in the upper limit of the normal reference
range. USPSTF recommendation level: I; evidence, poor
(2QEEE) (27).
2.1.3. PTU, if available, is recommended as the first-
line drug for treatment of hyperthyroidism during the first
trimester of pregnancy, because of the possible association
of MMI with specific congenital abnormalities that occur
during first trimester organogenesis. MMI may also be
prescribed if PTU is not available or if a patient cannot
tolerate or has an adverse response to PTU. MMI 10 mg
is considered to be approximately equal to 100–150mgof
PTU. Recent analyses reported by the FDA indicate that
PTU may rarely be associated with severe liver toxicity.
For this reason, we recommend that clinicians change
treatment of patients from PTU to MMI after the com-
pletion of the first trimester. Available data indicate that
MMI and PTU are equally efficacious in the treatment of
pregnant women. Practitioners should use their clinical
judgment in choosing the ATD therapy, including the
potential difficulties involved in switching patients
from one drug to another. If switching from PTU to
MMI, thyroid function should be assessed after 2 wk
and then at 2- to 4-wk intervals. USPSTF recommen-
dation level: B; evidence, fair (1QQEE). Although liver
toxicity may appear abruptly, it is reasonable to mon-
itor liver function in pregnant women on PTU every 3–4
wk and to encourage patients to promptly report any
new symptoms. USPSTF recommendation level: C; ev-
idence, poor (2QEEE) (28–34).
2.1.4. Subtotal thyroidectomymay be indicated during
pregnancy as therapy for maternal Graves’ disease if: 1) a
patient has a severe adverse reaction to ATD therapy; 2)
persistently high doses of ATD are required (over 30mg/d
of MMI or 450 mg/d of PTU); or 3) a patient is nonad-
herent to ATD therapy and has uncontrolled hyperthy-
roidism. The optimal timing of surgery is in the second
trimester. USPSTF recommendation level: C; evidence,
fair (2QEEE) (35–37).
2.1.5. There is no evidence that treatment of subclin-
ical hyperthyroidism improves pregnancy outcome, and
treatment could potentially adversely affect fetal out-
come. USPSTF recommendation level: C; evidence, fair
(2QEEE) (27, 38).
2.2.Management ofmaternal hyperthyroidism: fetal
aspects
2.2.1.Because thyroid receptorantibodies (thyroid recep-
tor stimulating,binding,or inhibitingantibodies) freelycross
the placenta and can stimulate the fetal thyroid, these anti-
bodies shouldbemeasuredby22wkgestationalage inmoth-
erswith: 1) currentGraves’ disease; or2) ahistoryofGraves’
disease and treatment with 131I or thyroidectomy before
pregnancy; or 3) a previous neonatewithGraves’ disease; or
4) previously elevated TRAb. Women who have a negative
TRAb and do not require ATD have a very low risk of fetal
or neonatal thyroid dysfunction. USPSTF recommendation
level: B; evidence, fair (1QQQE) (39–42).
2.2.2. 131I should not be given to a woman who is or
may be pregnant. If inadvertently treated, the patient
should be promptly informed of the radiation danger to
the fetus, including thyroid destruction if treated after the
12thweekof gestation.USPSTF recommendation level:A;
evidence, good (1QQQE).There arenodata foror against
recommending termination of pregnancy after 131I expo-
sure. USPSTF recommendation level: I; evidence, poor
(2QEEE) (43–47).
2.2.3. In women with TRAb or thyroid-stimulating Ig
elevated at least 2- to 3-fold the normal level, and in
women treated with ATD, maternal free T4 and fetal thy-
roid dysfunction should be screened for during the fetal
anatomy ultrasound (18th-22nd wk) and repeated every
4–6wkor as clinically indicated. Evidence of fetal thyroid
dysfunction could include thyroid enlargement, growth
restriction, hydrops, presence of goiter, advanced bone
age, tachycardia, or cardiac failure. If fetal hyperthy-
roidism is diagnosed and thought to endanger the preg-
nancy, treatment using MMI or PTU should be given
with frequent clinical, laboratory, and ultrasoundmon-
itoring. USPSTF recommendation level: B; evidence,
fair (1QQQE) (39, 41, 48–50).
2.2.4. Umbilical blood sampling should be consid-
ered only if the diagnosis of fetal thyroid disease is not
reasonably certain from the clinical and sonographic
data, and the information gained would change the
treatment. USPSTF recommendation level: B; evidence,
fair (2QEEE) (41, 51–56).
2.2.5. All newborns of mothers with Graves’ disease
(except thosewith negativeTRAbandnot requiringATD)
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should be evaluated by amedical care provider for thyroid
dysfunction and treated if necessary. USPSTF recommen-
dation level: B; evidence, fair (1QQQE) (40, 48, 52).
2.1.1–2.2.5. Background and evidence
The prevalence of hyperthyroidism in pregnancy
ranges from 0.1 to 0.4%,with Graves’ disease accounting
for 85%of cases (28, 57, 58). The activity level of Graves’
disease may fluctuate during gestation, with exacerbation
during the first trimester and improvement by late gesta-
tion. Hyperthyroidism of Graves’ disease may be aggra-
vated by high levels of hCG in the first trimester.
Because nonspecific symptoms of hyperthyroidism may
bemimicked by normal pregnancy, the presence of a goiter,
especially with a bruit or thrill, may point to a diagnosis of
true Graves’ disease. Thyroid function tests must be inter-
preted in the context of the normal gestational changes of
decreased serum TSH and increased T4 and T3 levels.
Patients suspected of having hyperthyroidism require
measurement of serum TSH, T4 or free T4, T3 levels, and
TRAb. However, interpretation of thyroid function tests
must bemade in relation to the hCG-mediated decrease in
serum TSH levels and the increase in T4 binding globulin
concentrations that occur during pregnancy (59–61). In
the normal pregnantwoman, TSH levels typically are sup-
pressed in the mid to late first trimester.
Fetal hyperthyroidism due to the transplacental pas-
sage of maternal TSH receptor stimulating antibody
(TRAb) levels is rare (0.01%of pregnancies), but it should
be considered in anywomanwith a past or current history
of Graves’ disease and may require treatment with mater-
nal antithyroid medications.
Maternal hyperthyroidism is associated with both ges-
tational and fetal risks that are related to the disease itself
and/or to the medical treatment of the disease. Inade-
quately treated maternal thyrotoxicosis is associated with
an increased risk of medically indicated preterm delivery,
intrauterine growth restriction and low birth weight, pre-
eclampsia, congestive heart failure, and fetal death (62). In
addition, overtreatment of the mother with thioamides
can result in iatrogenic fetal hypothyroidism (51), but un-
dertreatment of maternal hyperthyroidism may lead to
central congenital hypothyroidism (63, 64).
Fetal hyperthyroidismcanbe associatedwith intrauter-
ine growth restriction, fetal tachycardia, fetal goiter, ad-
vancedbone age, fetal hydrops, pretermdelivery, and fetal
death (40–42, 53, 56, 65). The diagnosis is suggested by
any of these signs or abnormalities.Maternal TRAb levels
able to induce fetal hyperthyroidism are usually over three
times the upper normal limit.
PTU and MMI or its derivative carbimazole are the
mainstays of treatment. Recently, the Adverse Event Re-
porting System of the FDA has focused attention on the
relation between hepatotoxicity and PTU (29). This find-
ing has led to a recommendation that PTU use in preg-
nancy be limited to the first trimester, and then treatment
be switched toMMI.Use ofMMIduring the first trimester
has been associated with a possible embryopathy.
3.0 Gestational hyperemesis and hyperthyroidism
Recommendations
3.1. Thyroid function tests (TSH, total T4, or free T4
index, or free T4) and TRAb should be measured in pa-
tients with hyperemesis gravidarum (5% weight loss, de-
hydration, and ketonuria) and clinical features of hyper-
thyroidism. USPSTF recommendation level: B; evidence,
fair (2QQEE) (24, 27, 66–68).
3.2. Most women with hyperemesis gravidarum, clin-
ical hyperthyroidism, suppressed TSH, and elevated free
T4 do not require ATD treatment. USPSTF recommenda-
tion level:A; evidence, good (1QQQQ). Clinical judgment
should be followed in women who appear significantly
thyrotoxic or who have in addition serum total T3 values
above the reference range for pregnancy. Beta blockers
such as metoprolol may be helpful and may be used with
obstetrical agreement. USPSTF recommendation level: B;
evidence, poor (2QEEE) (13, 25, 26, 66–68).
3.3. Women with hyperemesis gravidarum and diag-
nosed to have Graves’ hyperthyroidism (free T4 above
the reference range or total T4  150% of top normal
pregnancy value, TSH 0.01mIU/liter, and presence of
TRAb) will require ATD treatment, as clinically neces-
sary. USPSTF recommendation level: A; evidence, good
(1QQQQ) (13, 25, 26, 66–68).
3.1–3.3 Background and evidence
Gestational hyperthyroidism (GH), also referred as
gestational thyrotoxicosis or gestational transient thyro-
toxicosis, is defined as transient hyperthyroidism, limited
to the first half of pregnancy, characterized by elevated
serum free T4 and suppressed or undetectable serumTSH,
in the absence of thyroid autoimmunity. GH is typically
associated with hyperemesis gravidarum, defined as se-
vere vomiting in early pregnancy that causes more than
5%weight loss, dehydration, and ketonuria and occurs in
0.5–10 cases per 1000 pregnancies. The etiology of thy-
roid stimulation is thought to be hCG itself, or molecular
variant proteins related to hCG. Multiple gestation is an-
other recognized cause of GH. Very high elevations of
hCGoccurring in patientswith hydatidiformmole or cho-
riocarcinoma are often associated with clinical hyperthy-
roidism. TSHR mutations with functional hypersensitiv-
ity to hCG have also been recognized as a rare cause of
severe GH. Other isolated rare cases of GH, such as hy-
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perplacentosis and hyperreactio luteinalis, have been re-
ported.The condition can cause severemorbidity andmay
require frequent visits to the emergency room or admis-
sion to the hospital for management of dehydration, elec-
trolyte abnormalities, psychological support, and occa-
sionally parenteral nutrition (25, 26).
In women with GH, the serum TSH is suppressed or
undetectable; serum total T4 and free T4 are elevated, but
the free T3 is elevated less frequently. Women with hyper-
emesis and elevated thyroid hormone levels most com-
monly do not have other clinical evidence of Graves’ dis-
ease and lack the TSH receptor antibodies typically
present in Graves’ disease. A small portion of these pa-
tients have clinical hyperthyroidism.Clinical symptomsof
hyperthyroidism antedating pregnancy, the presence of
goiter, ophthalmopathy, and laboratory evidence of auto-
immunity favor the diagnosis of Graves’ hyperthyroidism.
Because many common signs and symptoms of hyperthy-
roidismmay bemimicked by normal pregnancy, the clinical
challenge is to differentiate these disorders (13, 25, 26, 66–
68). There is disagreement as to whether thyroid hormone
should be measured in all pregnancies with hyperemesis, or
only when clinical features of hyperthyroidism are present.
Some authorities suggest that measurement of thyroid func-
tion tests may safely be limited to those womenwith clinical
evidence suggestive of hyperthyroidism.
There is no clear evidence in the medical literature that
patients diagnosed with GH have benefited from antithy-
roid therapy, but only a few patients have been reported
who received ATD for a few weeks. The available data
indicate that most women with hyperemesis, with no or
mild clinical evidence of hyperthyroidism, suppressed
TSH, and elevated free T4, remit spontaneously. No clear
data are available to support the use of ATD in the man-
agement ofwomenwithGH, but clinical judgment should
be followed inwomenwith clear signs of hyperthyroidism
and elevated free T4 and free T3, or total T3 above the
normal pregnancy range (13, 25, 26, 66–68).
4.0. Autoimmune thyroid disease and miscarriage
Recommendations
4.1. A positive association exists between the presence
of thyroid antibodies and pregnancy loss. Universal
screening for antithyroid antibodies, and possible treat-
ment, cannot be recommended at this time. As of January
2011, only one randomized interventional trial has sug-
gested a decrease in the first trimester miscarriage rate in
euthyroid antibody-positive women, but treatment dura-
tion was very brief before the outcome of interest. How-
ever, because women with elevated anti-TPO antibodies
are at increased risk for progression of hypothyroidism, if
identified such women should be screened for serum TSH
abnormalities before pregnancy, as well as during the first
and second trimesters of pregnancy. USPSTF recommen-
dation level: C; evidence, fair (2QEEE) (69–72).
4.1. Background and evidence
A 2- to 5-fold increased risk of miscarriage has been
found in unselected populations of euthyroidwomenwith
autoimmune thyroid disease (70).Most but not all studies
have also demonstrated an association between thyroid
antibodies and recurrentmiscarriage in euthyroid patients
(69, 71).However, the data are imperfect because the tim-
ing of sample collection for thyroid antibody measure-
ment was not always specified, the prevalence of thyroid
antibodies varied widely, and studies measured TPO-Ab
or TGAb or both. In some of these reports, thyroid anti-
bodies may simply serve as a marker for generalized au-
toimmunedisease.TSH levels havebeen found slightly but
significantly higher (within the normal range) in euthyroid
women with thyroid autoimmunity than in those women
without it. In some of these studies, women with thyroid
antibodies were older than those without antibodies.
Thedataare less clearon themiscarriage rate in infertile
patients undergoing assisted reproductive technology, ac-
cording to the presence or absence of thyroid antibodies.
Half of the studies find that the presence of thyroid anti-
bodies is associated with a 2-fold increased risk for spon-
taneous miscarriage in euthyroid women undergoing in
vitro fertilization (73, 74). No significant difference was
found in the other studies, but in some a trend toward a
higher miscarriage rate was noticed in the thyroid anti-
body-positive women. The largest series, although retro-
spective, failed to demonstrate an adverse effect on mis-
carriage rates in antibody-positive vs. antibody-negative
womenundergoing assisted reproductive technology (73).
It is not possible to draw a definitive conclusion based on
available data.
Treatment
Negro et al. (72) performed a prospective, randomized
trial of 984unselectedwomenwhowere screened forTPO
antibody positivity and thyroid function tests on their first
obstetrical visit. The 115 women who were TPO-Ab
were divided into two groups: group A (n 57) included
TPO-Ab women treated with levothyroxine; group B
(n  58) included TPO-Ab women who received no
levothyroxine intervention. Group C (n 869) consisted
of all TPO-Abwomen, none of whom received levothy-
roxine. The first trimester miscarriage rate was signifi-
cantly lower in groups A (3.5%) and C (2.4%) than in
group B (13.8%) (P  0.05). However, the mean gesta-
tional age at the time ofmiscarriagewas 8.5wk, and treat-
ment on average did not start until 10.5 wk gestation
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(40%on treatment by 8wk and 79%by 12wk). It should
also be taken into account that TSH levels during preg-
nancy were significantly higher, whereas free T4 levels
were significantly lower (although in the normal range) in
group B than in group C.
In a retrospective study in Belgium, 42 TPO-Ab pa-
tients received levothyroxine treatment during pregnancy,
and their evolution was compared with 709 TPO-Ab
women. No significant differences in the obstetrical com-
plications rate were observed between the groups, but
early miscarriages were not investigated in this study. A
further limitation to this study is that a TPO-Ab group
without levothyroxine treatment was not included (75).
Regarding medical intervention in thyroid antibody-
positive women with recurrent abortion, the studies re-
viewed demonstrate that T4 or iv Ig treatments may
decrease the miscarriage rate (64–74, 75, 78). How-
ever, many of these women had evidence of other au-
toimmunity, and limitations in the design of each study
preclude any conclusion regarding the efficacy of med-
ical intervention.
A single study has evaluated the impact of T4 therapy in
euthyroid antibody-positive infertile women who under-
went assisted reproduction techniques (73). Although the
miscarriage rate was lower in women who received T4
(33%) than in those who did not (52%), this difference
failed to reach statistical significance (a failing that may
have been secondary to the small sample size).
Women with recurrent pregnancy loss are reported
to have lower selenium levels in hair and in red blood
cells (77). Selenium substitution and treatment with sel-
enomethionine may decrease TPO-Ab levels in euthy-
roid subjects (78). Large randomized studies are needed
to assess the contribution of selenium in the etiology of
recurrent pregnancy loss and the potential benefits of its
supplementation.
Besides the risk of miscarriages, thyroid autoimmunity
may be correlated with a higher frequency of preterm de-
liveries (between 2- and 3-fold higher than in pregnancy
without thyroid antibodies) and lowbirthweight.Accord-
ing to a study by Negro et al. (72) in Italy, the preterm
delivery rate was higher (22.4%) in TPO-Ab women
without treatment than in TPO-Ab women on levothy-
roxine treatment (7%) or in TPO-Ab women (8.2%)
(P  0.05), although the gestational age at delivery was
not specified between the groups.
Recently, 9247 singleton pregnancies were prospec-
tively studied in Finland. Perinatal mortality was 2- to
3-fold greater in women who were TPO-Ab or TG an-
tibody positive in the first trimester as compared with
those who were antibody negative, but most of these in-
fants were also born preterm (79).
Intellectual and motor development score evaluations
were performed at 25–30 months of age on the children
from34 euthyroidmotherswith elevated titers ofTPO-Ab
at16–20wkgestation.Themean intelligence scorewas10
points lowerand themeanmotor score9points lower than
those of the controls (P  0.001 and P  0.001, respec-
tively) (80). More studies are necessary to confirm
whether thyroid autoimmunity could be considered a risk
factor for impairedneurodevelopment, independentof the
thyroid function.
5.0 Thyroid nodules and cancer
Recommendations
5.1. FNA cytology should be performed for predomi-
nantly solid thyroid nodules greater than 1 cm discovered
in pregnancy. Women with nodules 5 mm to 1 cm in size
should be considered for FNA if they have a high-risk
history or suspicious findings on ultrasound, and women
with complex nodules 1.5–2 cm or larger should also re-
ceive an FNA. During the last weeks of pregnancy, FNA
can reasonablybedelayeduntil after delivery.Ultrasound-
guided FNA is likely to have an advantage formaximizing
adequate sampling. USPSTF recommendation level: B; ev-
idence, fair (1QQQE) (81–84).
5.2. When nodules discovered in the first or early sec-
ond trimester are found to be malignant or highly suspi-
cious on cytopathological analysis, to exhibit rapid
growth, or to be accompanied by pathological neck ade-
nopathy, pregnancy need not be interrupted, but surgery
should be offered in the second trimester. Women found
tohave cytology indicative of papillary cancer or follicular
neoplasm without evidence of advanced disease and who
prefer to wait until the postpartum period for definitive
surgery may be reassured that most well-differentiated
thyroid cancers are slow growing and that delaying sur-
gical treatment until soon after delivery is unlikely to
change disease-specific survival. USPSTF recommenda-
tion level: B; evidence, fair (1QQEE) (75, 83–85).
5.3. It is appropriate to administer thyroid hormone to
achieve a suppressed but detectable TSH in pregnant
women with a previously treated thyroid cancer, in those
with an FNA positive for or suspicious for cancer, or in
those who elect to delay surgical treatment until postpar-
tum. High-risk patients may benefit more than low risk
patients from a greater degree of TSH suppression. The
free T4 or total T4 levels should ideally not be increased
above the normal range for pregnancy. USPSTF recom-
mendation level: I; evidence, poor (QEEE) (86).
5.4. RAI with 131I should not be given to womenwho
are breastfeeding or for at least 4 wk after nursing has
ceased. USPSTF recommendation level: A; evidence,
good (1QQQQ). Furthermore, pregnancy should be
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avoided for 6 months to 1 yr in women with thyroid
cancer who receive therapeutic RAI doses to ensure sta-
bility of thyroid function and confirm remission of thy-
roid cancer. USPSTF recommendation level: B; evi-
dence, fair (1QQEE) (87–89).
5.1.–5.4 Background and evidence
There is biological plausibility that pregnancy could pro-
mote the onset of growth of a benign or malignant nodule
due to a pregnancy-induced relative iodine deficiency, the
thyroid-stimulating effect of hCG, and high estrogen levels.
Only data from areas of mild iodine insufficiency are avail-
able and suggest that nodules may be more prevalent in
pregnant women and that the volumemay increase in ges-
tation (82). Several retrospective studies reported a ma-
lignancy rate of about 15%, with one exceptional study
finding of 50% (90), and these limited data suggest that
the malignancy rate is either similar to or possibly greater
than that seen in the general population.
The diagnostic evaluation of a single thyroid nodule or
a nodule found in amultinodular goiter discovered during
pregnancy should be similar to that of nonpregnant pa-
tients (75, 91) and relies primarily on the results of thyroid
ultrasound and FNA biopsy. Nodules suspected to be hy-
perfunctioning may await further assessment with a ra-
dionuclide scan until postpartum. For the rare nodule
causing severe hyperthyroidism, ATD treatment and op-
eration may be advisable. Evaluating the nodule during
pregnancy is often helpful to the mother in making deci-
sions regarding breastfeeding and the potential need for
postpartumadjunctive therapywith radioiodine after sur-
gical removal of a cancer.
There is no clear evidence that pregnancy worsens the
survival from well-differentiated thyroid cancer found
during an existing pregnancy (75, 92). However, if the
result of FNA is consistent with or highly suggestive of
papillary, follicular, anaplastic, or medullary carcinoma,
or has suspicious sonographic characteristics, surgery
should be offered in the second trimester. During the first
trimester, there is concern over the possible teratogenic
effects on the fetus, and surgery of any type is associated
with increased early fetal loss (93). Surgery in the third
trimester is associated with a higher incidence of preterm
labor. Fetal loss or significant complications are rare in the
second trimester (93). There is some evidence that thyroid
cancers discovered during pregnancy have a greater
chance of recurrence when defined by increasing serum
markers ofTGorTGantibodies (94).However, operation
for papillary cancermaybepostponedwith little increased
risk until after delivery if the patient is hesitant to undergo
surgery during pregnancy (75, 91–93), and there are no
data that surgery undergone during pregnancy as com-
pared with immediately postpartum affects survival.
If anodule suspiciousof cancer is discovered in the third
trimester, further workup and treatment can be delayed
until after delivery unless the nodule is rapidly growing or
associated with a poor prognosis. Exogenously adminis-
tered thyroid hormone is recommended for suspicious or
malignant nodules to achieve a suppressedTSHwith a free
T4 or total T4 in the upper normal range for pregnancy to
avoid both maternal and fetal complications.
Several series have examined the natural history of can-
cer recurrence in women who became pregnant after re-
ceiving successful treatment for thyroid cancer, and in all
studies there was no evidence that thyroid cancer was ad-
versely influencedby the pregnancy (95).Monitoringwith
TG is recommended for women who have received RAI,
andwomenmay bemaintained on suppressive doses of T4
that do not cause overt hyperthyroidism.
Multiple studies have indicated that prior treatment with
131I does not appear to affect subsequent pregnancy out-
comes including infertility, congenital malformations, mis-
carriages, stillbirths, prematurity, low birth weight, infant
mortality, the rate of nonthyroidal malignancy in the off-
spring, or intellectual development (96). However, nursing
women should not be offered 131I therapy because of the
concentration of isotope in the lactating breast and transfer
of the isotopetothe infant.Conceptionshouldbeavoidedfor
at least1yrafter 131I ablative treatment to confirmremission
of thyroid cancer and stability of thyroid function tests (87).
6.0. Iodine nutrition during pregnancy
Recommendations
6.1. Women in the childbearing age should have an
average iodine intake of 150 g/d. As long as possible
before pregnancy and during pregnancy and breastfeed-
ing, women should increase their daily iodine intake to
250 g on average. USPSTF recommendation level: A;
evidence, good (1QQQE) (59, 97–99).
6.2. Iodine intake during pregnancy and breastfeeding
should not exceed twice the daily RNI for iodine, i.e. 500
g iodine per day. USPSTF recommendation level: I; ev-
idence, poor (2QEEE) (59, 97–99).
6.3. Although not advised as a part of normal clinical
practice, the adequacy of the iodine intake during preg-
nancy can be assessed by measuring UIC in a representa-
tive cohort of the population. UIC should ideally range
between 150 and 250 g/liter. If there is significant con-
cern, the caregiver shouldassayTSHand thyroidhormone
levels. USPSTF recommendation level: A; evidence, good
(1QQQQ).
6.4. To reach the daily recommended nutrient intake
for iodine, multiple means must be considered, tailored
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to the iodine intake level in a given population. Differ-
ent situations must therefore be distinguished: 1) coun-
tries with iodine sufficiency and/or with a well-estab-
lished USI program; 2) countries without a USI program
or with an established USI program where the coverage
is known to be only partial; and 3) remote areas with no
accessible USI program and difficult socioeconomic
conditions. USPSTF recommendation level: A; evi-
dence, good (1QQQQ) (100–104).
6.5. We recommend that once-daily prenatal vitamins
should contain 150–200 g iodine and that this be in the
form of potassium iodide or iodate, the content of which is
verified to ensure that all pregnant women taking prenatal
vitamins are protected from iodine deficiency. Ideally, sup-
plementation should be started before conception. Prepara-
tions containing iron supplements should be separated from
thyroid hormone administration by at least 4 h. USPSTF
recommendation level: B; evidence, fair (2QQEE) (105).
6.6 We recommend that breastfeeding women main-
tain a daily intake of 250g of iodine to ensure that breast
milk provides 100g iodine per day to the infant. USPSTF
recommendation level: A; evidence, good (1QQQE).
6.1.–6.6. Background and evidence
Iodine is essential for the synthesis of T4, a critical hor-
mone for fetal brain development.Maternal T4 is the only
source of hormone before the development of the fetal
thyroid at 13–15 wk gestation; maternal iodine is still re-
quired for fetal thyroidhormone synthesis thereafter.Dur-
ing pregnancy, thyroid hormone synthesis increases by
20–40%, compensating for estrogen-induced T4 binding
globulin and increased iodine clearance. Therefore, ma-
ternal iodine intake must be increased during pregnancy.
Iodine stores should be replete at conception with an io-
dine intake of more than 150 g/d (97).
Worldwide, iodine deficiency is the leading cause of
preventable fetal brain damage (98, 106). Severe iodine
deficiency causes endemic goiter, hypothyroidism, cretin-
ism, decreased fertility,miscarriage, increased infantmor-
tality, trophoblastic or embryonic fetal disorders, and
mental retardation (99). Even mild to moderate iodine
deficiency during pregnancy can lead to increased TSH
levels and may cause both maternal and fetal goiter (98).
Mildmaternal subclinical or overt hypothyroidism due to
iodide deficiency may result in intellectual deficit and/or
neuropsychomotor deficits in offspring. These problems
may be prevented if iodine supplementation is started in
early pregnancy (100).
Breastfed infants are dependent upon maternal iodine
intake. The mammary gland concentrates iodine, and
breast milk supplies 100 g/d to the infant. Mothers
should continue to have an intake of 250g iodide per day
during lactation. A World Health Organization expert
panel (97) recommended iodine intakeof200–300g/d in
pregnant and breastfeeding women, based on population
studies, noting prevention of maternal hypothyroidism
and goiter and fetal goiter.
Environmental iodine varies widely geographically, as
does iodine supplementation of food, salt, or oil. The best
parameter to evaluate the adequacy of iodine nutrition in
a population is urinary iodine excretion (UIE). During
pregnancy, the UIE should be 150–250 g/d (97, 100).
Although UIE is useful for health population studies, it is
not a valid diagnostic criterion in individuals.
The prevalence of iodine deficiency (UIE  100 g/d)
ranges from 11% in North and South America to 42% in
some parts of Africa, and as high as 50% in some parts of
Europe and China (107). Recent surveys of iodine nutri-
tion in pregnant women are limited, and a global estimate
of the prevalence of iodine deficiency in pregnancy is not
possible (105). More recent surveys of urinary iodine in
limited geographical areas continue to reveal significant
numbers of women with suboptimal iodine nutrition, de-
fined as urinary iodine less than 150 g/liter during preg-
nancy, even in areas where iodization of salt has been
implemented (97, 105).
In the United States, overall urinary iodine declined
substantially from the 1970s to the 1990s, but stabilized
at 168 g/liter in 2002 and 160 g/liter in 2002–2004.
Concomitantly, the mean urinary iodine in pregnant
women in the United States decreased from 327 g/liter
to 140g/liter from 1971–1974 to 1988–1994, with an
increase in the prevalence of moderately low urine io-
dine concentrations (50 g/liter) from 0.6 to 1.9%
(108). The most recent National Health and Nutrition
Examination Survey data for pregnant women in the
United States note stability of median urinary iodine in
pregnancy from 141 g/liter (1988–1994), 173 g/liter
(2001–2002), and 181 g/liter (2003–2004), but with a
substantial number of women still having low urine io-
dine (21% 100g/liter and 4.7% 50g/liter) at the
most recent report (97, 108, 109).
In an individual pregnant woman, the best surrogate to
determine iodine sufficiency is maternal thyroid function.
Iodine restriction during pregnancy results in reduction of
free T4 and increases in TSH, TG, T3/T4 ratio, and thyroid
volume, with goiter formation in both the mother and
fetus. However, Hollowell and Haddow (99) found no
evidence of low T4 or high (4.5mIU/liter) TSH values in
a small sample of U.S. pregnant women with urinary io-
dine less than 50 g/liter.
The recommended method for correcting iodine defi-
ciency worldwide is USI, but in some countries where USI
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cannot be implemented, massive annual doses of slow-
release iodinated oil are given to children and towomen in
the reproductive age group. Four hundred milligrams of
oral iodine will cover the thyroidal needs for an adult for
about a 1-yr period (99).
Fortification should begin as soon as possible in a preg-
nant woman, ideally no later than the first trimester to
allow rapid adaptation to the increased needs of preg-
nancy. It is important to note that even in a population
judged to be iodine sufficient, individualwomenmayhave
inadequate iodine intake before and during pregnancy,
thus emphasizing the need for routine supplementation of
all pregnant women with adequate iodine in the form of
prenatal vitamins. Women should be counseled to take
prenatal supplements containing the RNI for pregnancy
and to ascertain that their vitamin preparations in fact do
contain adequate amounts of iodine. Supplementation
should begin as soon as pregnancy is confirmed.
Excess iodine intake may, paradoxically, lead to an in-
crease in hypothyroidism in subjects at risk for autoim-
mune thyroiddisease and tohyperthyroidism,particularly
when iodine is newly introduced in populations with pre-
vious iodine deficiency and multinodular goiters. Excess
iodine is empirically defined as double the RNI (110).
7.0. Postpartum thyroiditis
Recommendations
7.1.There are insufficientdata to recommendscreening
of all women for PPT. USPSTF recommendation level: I;
evidence, poor (2QEEE) (111, 112).
7.2. Women known to be TPO-Ab should have TSH
measured at 6–12 wk gestation and at 6 months postpar-
tum, or as clinically indicated. USPSTF recommendation
level: A; evidence, good (1QQQE) (112–116).
7.3. Because the prevalence of PPT inwomenwith type
1 diabetes, Graves’ disease in remission, and chronic viral
hepatitis is greater than in the general population, screen-
ing by TSH is recommended at 3 and 6 months postpar-
tum. USPSTF recommendation level: B; evidence, fair
(2QQEE).
7.4. Women with a history of PPT have a markedly
increased risk of developing permanent primary hypo-
thyroidism in the 5- to 10-yr period after the episode of
PPT. An annual TSH level should be performed in these
women. USPSTF recommendation level: A; evidence,
good (1QQQE) (113, 117–119).
7.5. Asymptomatic women with PPT who have a TSH
above the reference range but less than 10 mIU/liter and
who are not planning a subsequent pregnancy do not nec-
essarily require intervention, but should, if untreated, be
remonitored in 4–8 wk.When a TSH above the reference
range continues, women should be treated with levothy-
roxine. Symptomatic women and women with a TSH
above normal and who are attempting pregnancy should
be treated with levothyroxine. USPSTF recommendation
level: B; evidence, fair (2QQEE) (112).
7.6. There is insufficient evidence to conclude whether
an association exists between PPD and either PPT or thy-
roid antibody positivity (in women who did not develop
PPT). USPSTF recommendation level: I; evidence, poor
(2QEEE). However, because hypothyroidism is a poten-
tially reversible cause of depression, women with PPD
should be screened for hypothyroidism and appropriately
treated. USPSTF recommendation level: B; evidence, fair
(2QQEE) (120–126).
7.1.–7.6. Background and evidence
PPT is the occurrence of thyrotoxicosis, hypothyroid-
ism, or thyrotoxicosis followed by hypothyroidism in the
first year postpartum in women who were without clini-
cally evident thyroid disease before pregnancy. It is be-
lieved tobe causedbyanautoimmunity-induceddischarge
of preformed hormone from the thyroid. PPT occurs al-
most exclusively in women who are thyroid antibody
positive.
Prevalence in unselected populations. The reported prev-
alence of PPT varies globally, and the mean prevalence in
prospective studies in iodine-sufficient areas in which at
least two thirds of the cohort was followed for at least 5
months postpartum is approximately 7%(127). Incidence
is affected by genetic influences and iodine intake.
Prevalence inwomenwith type 1 diabetesmellitus (DM).
The prevalence of TPO antibodies in patients with type 1
DM reported in the Familial Autoimmune and Diabetes
Studywas26.6%. Inaccordwith this, the incidenceofPPT
in women with type 1 DM is higher than in an unselected
population, with a range of 18–25% (114).
Predictors of PPT. PPT is caused by the immunological
perturbations that occur during pregnancy and postpar-
tum. Some of the immunological abnormalities are ob-
served before the onset of thyroid dysfunction (128).
Among these, TPO-Abpositivity is themost usefulmarker
for the prediction of postpartum thyroid dysfunction
(129). From 40–60%of womenwith positive TPO-Ab in
early pregnancy develop postpartum thyroid dysfunction
(112, 123). The majority of mothers with high titers of
antibody develop postpartum thyroid dysfunction (129).
ThyrotoxicsymptomsofwomenwithPPT.Thethyrotoxic
phase of PPT occurs between 1 and 6 months postpartum
(most commonly at 3 months) and usually lasts only 1–2
months. It is important to differentiate between the thy-
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rotoxic phase of PPT and Graves’ disease presenting de
novo in the postpartum period. Symptoms during the thy-
rotoxic phase of PPT tend to be milder than during hy-
perthyroidism due to Graves’ disease. Furthermore, 95%
ofwomenwithGraves’ disease areTSH receptor antibody
positive. In contrast to Graves’ disease, PPT is character-
izedbydecreasedRAIuptake (measurementof 131I uptake
is contraindicated in lactating women). From 20–30% of
patients who develop PPT have only thyrotoxic symp-
toms. Fatigue, palpitations, weight loss, heat intolerance,
nervousness, anxiety, and irritability aremoreprevalent in
women with PPT than in euthyroid women (129). The
frequency of asymptomatic hyperthyroidism among pa-
tients with PPT is approximately 30% (112).
Hypothyroid symptoms of women with PPT. The hypo-
thyroid phase of PPT usually occurs between 3 and 8
months (most commonly at 6 months). Approximately
40–45% of women who develop only the hypothyroid
phase of PPTwill experience symptoms,whereas 25–35%
of women who develop hypothyroidism after the hyper-
thyroid phase will experience hypothyroid symptoms
(130). Hypothyroidism tends to happen earlier when pre-
ceded by thyrotoxicosis than when it occurs alone. The
hypothyroid phase usually lasts 4–6 months. In system-
atic studies, fatigue, loss of concentration, poor memory,
constipation, and possibly depression were most fre-
quently experienced (128, 129).
Association of PPT with PPD. The incidence of PPD in non-
selectedpopulationsusingDiagnosticandStatisticalManualof
Mental Disorders, Third Edition-Revision (DSMIII-R) criteria
appears to be approximately 10% (120). Several studies have
addressed whether there is an association between PPD and
positive thyroid antibody status alone, in addition to the possi-
ble association between PPD and women who have PPTwith
thyroid dysfunction. At present, reported studies have not re-
vealed a consistent association between PPDand either PPTor
thepresenceof thyroidantibodypositivity ineuthyroidwomen
postpartum.
Optimal treatment forPPT.Therehavebeennocontrolled
studies evaluating the optimal treatment for PPT. In the
thyrotoxic phase of PPT, intervention with propranolol
was recommended for women with symptoms of palpita-
tions, fatigue, heat intolerance, and/ornervousness.Treat-
ment decisions for women in the hypothyroid phase of
PPT depend on both the degree of hypothyroidism and
whether the woman is attempting pregnancy. Asymptom-
atic womenwho are not planning a subsequent pregnancy
andwhose TSH level is between 4 and 10mIU/liter do not
necessarily require intervention and should, if untreated,
be reevaluated in 4–8 wk. When a TSH above the refer-
ence range continues postpartum, women should be
treated with levothyroxine. Women with a TSH between
4and10mIU/literwhoare either symptomatic or attempt-
ing to become pregnant should be treated with T4.
Follow-up for womenwith PPT. Postpartum thyroid dys-
function is typically transient in nature, with the majority
of women returning to euthyroidism by the end of the first
postpartum year. However, even after recovery from hy-
pothyroidism, abnormalities in ultrasonography and/or
iodide perchlorate discharge tests persist, reflecting un-
derlying chronic autoimmune thyroiditis. It is therefore
not surprising that a small percentage of women never
recover from the initial hypothyroid phase, and 20–64%
of women develop permanent hypothyroidism during
long-term follow-up (117, 119).
8.0. Screening for thyroid dysfunction during
pregnancy
Recommendations
8.1a. Universal screening of healthy women for thyroid
dysfunctionbeforepregnancy is not recommended.USPSTF
recommendation level: I; evidence, poor (2QEEE).
8.1b. However, caregivers should identify individuals at
“high risk” for thyroid illness (Table 1) on the basis of their
medical history, physical exam, or prior biochemical data.
When such individuals are identified, prenatalmeasurement
of serum TSH is recommended. If it is above 2.5 mIU/liter,
the test should be confirmed by repeat assay. Although no
randomized controlled trials are available to guide a re-
sponse, the committee believes it is appropriate to give low-
dose T4 treatment to bring TSH below 2.5 mIU/liter. This
treatmentcanbediscontinued if thewomandoesnotbecome
pregnant or postpartum. USPSTF recommendation level: I;
evidence, poor (2QEEE) (22, 131–133).
TABLE 1. Recommended patient profiles for targeted
thyroid disease case finding in women seeking
pregnancy or newly pregnant
Women over age 30 yr
Women with a family history or autoimmune thyroid disease or
hypothyroidism
Women with a goiter
Women with thyroid antibodies, primarily thyroid peroxidase
antibodies
Women with symptoms or clinical signs suggestive of thyroid
hypofunction
Women with type 1 DM or other autoimmune disorders
Women with infertility
Women with a prior history of miscarriage or preterm delivery
Women with prior therapeutic head or neck irradiation or prior
thyroid surgery
Women currently receiving levothyroxine replacement
Women living in a region with presumed iodine deficiency
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8.2a. All women considering pregnancy with known
thyroid dysfunction and receiving levothyroxine should
be tested for abnormal TSH concentrations before preg-
nancy. USPSTF recommendation level: B; evidence, fair
(1QQEE) (134, 135).
8.2b. If hypothyroidism has been diagnosed before
pregnancy, we recommend adjustment of the preconcep-
tion T4 dose to reach before pregnancy a TSH level not
higher than 2.5mIU/liter. USPSTF recommendation level:
C; evidence, fair (2QQEE) (132–134, 136).
8.2c. All women receiving levothyroxine should be ver-
bally screened prenatally to assess their understanding of
changing levothyroxine requirements after conception.
These women should be counseled to contact a physician
or medical professional immediately upon a missed men-
strual cycle or suspicion of pregnancy to check their serum
TSH level. An additional recommendation may be to in-
crease their levothyroxine dose by 30%, which is often
two additional tablets per week (nine tablets per week
instead of seven tablets), until their serum TSH can be
checked. USPSTF recommendation level: B; evidence, fair
(2QQEE) (12–14, 135).
8.3a. Universal screening for the presence of anti-TPO
antibodies either before or during pregnancy is not rec-
ommended. USPSTF recommendation level: C; evidence,
fair (2QEEE).
8.3b. However, women with elevated anti-TPO an-
tibodies are at increased risk for miscarriage, preterm
delivery, progression of hypothyroidism, and PPT.
Therefore, if identified, such women should be screened
for serum TSH abnormalities before pregnancy, as well
as during the first and second trimesters of pregnancy.
USPSTF recommendation level: C; evidence, fair
(1QQEE) (72, 132) (see also Section 8.5).
8.4a. The committee could not reach agreement with
regard to screening recommendations for all newly preg-
nant women. Two versions are therefore presented.
8.4a1. Some members recommended screening of all
pregnant women for serum TSH abnormalities by the
ninth week or at the time of their first visit. USPSTF rec-
ommendation level: C; evidence, fair (2QQEE) (6, 9, 22,
72, 137) (Authors supporting: L.D.G., J.R., J.H.L., N.A.,
C.J.E.).
8.4a2. Some members recommended neither for nor
against universal screeningof all pregnantwomen forTSH
abnormalities at the timeof their first visit. Thesemembers
strongly support aggressive case finding to identify and
test high-risk women (Table 1) for elevated TSH concen-
trations by the ninth week or at the time of their first visit
before or during pregnancy, and they recognize that in
some situations ascertainment of the individual’s risk sta-
tus may not be feasible. In such cases, and where the local
practice environment is appropriate, testing of all women
by wk 9 of pregnancy or at the first prenatal visit is rea-
sonable. USPSTF recommendation level: I; evidence, poor
(2QEEE) (72, 80, 137, 138) (Authors supporting:M.A.,
E.K.A., J.M., L.B., S.S., S.J.M., D.L., R.H.C.).
8.4b. If serumTSH is greater than 2.5mIU/liter at the
time of testing (or 3.0 mIU/liter in the second trimes-
ter), levothyroxine therapy should be instituted. For
overt hypothyroidism, USPSTF recommendation level:
A; evidence, good (1QQQQ); for SCH and obstetrical
outcome, USPSTF recommendation level: C; evidence,
fair (2QQEE); and for SCH and obstetrical outcome,
USPSTF recommendation level: C; evidence, poor
(2QEEE) (4, 5, 9, 131, 137).
8.4c. If TSH concentration is 2.5–10 mIU/liter, a start-
ing levothyroxine dose of 50 g/d or more is recom-
mended. Other thyroid preparations (such as T3) are not
recommended. USPSTF recommendation level: C; evi-
dence, fair (2QQEE) (135).
8.5. Women at high risk for PPT in the postpartum
months should be screened via assessment of serum TSH.
These high-risk groups include: 1) women known to be
TPOAb; 2) women with type 1 diabetes; and 3) women
with a prior history of PPT. Screening should occur at
6–12 wk postpartum. Women with Graves’ disease who
enter remission during pregnancy should be screened for
recurrence by TSH assay at 3–6 months. USPSTF recom-
mendation level: C; evidence, poor (2QEEE) (112–114)
(see also Section 7).
8.1.–8.5. Background and evidence
Thyroid dysfunction (hypothyroidism, hyperthyroid-
ism, and thyroid autoimmunity) during pregnancy can re-
sult in serious complications for both mother and infant
(4, 6, 9, 131, 137). For women with undiagnosed thyroid
disease, a screening test may identify dysfunction, allow-
ing the institution of interventions such as levothyroxine
therapy. The multitude of adverse outcomes linked to un-
treated thyroid disease during pregnancy (particularly re-
lating to hypothyroidism) leads to consideration of the
potential benefit and costs of screening for thyroid dys-
function before or during pregnancy.
The frequency of thyroid disease during pregnancy and
postpartum is sufficient to support consideration for
screening to detect abnormal TSH concentrations (19,
131, 137). Overt hypothyroidism occurs in 0.3–0.5% of
pregnancies and SCH in 2–4%of pregnancies (5, 6, 9, 70,
72). Numerous studies document an adverse impact on
pregnancy (and fetal well-being) when thyroid dysfunc-
tion (particularly hypothyroidism) or TPO antibodies are
detected (5, 6, 9, 69, 70, 131). Optimal treatment of ma-
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ternal overt hypothyroidism prevents these complications
(9, 72, 139).
Maternal SCH is associatedwith increased incidence of
adverse outcomes of pregnancy including preterm deliv-
ery, placental abruption, respiratory distress, early preg-
nancy loss, and admissions to the intensive care unit (4, 5,
21, 81, 137). Randomized, prospective study documents
an increase in pregnancy complications among women
with elevated serum TSH concentrations of 2.5–5.0 mIU/
liter in the first trimester without TPO antibodies (138).
These data are supported by other retrospective analysis
(131). Correction of hypothyroidismbefore pregnancy re-
stores the pregnancy outcomes to the rate seen in euthy-
roid TPO-Ab women (133, 139).
Although the majority of large-scale, well-designed
studies depict a consistent adverse impact from mild to
moderatematernal hypothyroidism, some studies are con-
tradictory (9, 80). Noting that modest discordance exists
in the published literature, the task force feels that the
majority of available, high-quality data do support the
finding that both subclinical and overt hypothyroidism
increase the risk of adverse pregnancy outcomes.
Of separate concern, although of equal importance, is
the potential for maternal hypothyroidism to also ad-
versely affect fetal cognitive development. Several retro-
spective studies document danger to the developing fetal
brain from both overt and subclinical maternal hypothy-
roidism (6, 22).
Two recent reports focus on the issue of treatment of
SCHand screening. The primary endpoint of the report by
Negro et al. (137) indicates that universal screening by 9
wk had no benefit on the overall outcome of the total
screened vs. nonscreened populations. However, in their
study individuals considered high risk were tested and
treated in both populations. When the screened and de-
tected “low-risk” pregnancies were compared with the
low-risk hypothyroid patients diagnosed after pregnancy,
there was a significant reduction in adverse outcomes.
Still, it must be noted that screening was done at an early
time (about 9 wk) and that the comparison groups had
both SCH and positive anti-TPO-Ab.
Information on effects of screening and treatment in
relation to neural development are sparse. Correction of
iodine deficiency during pregnancy prevents adverse fe-
tal neural development (see Section 6). In the “CATS”
study recently published by Lazarus et al. (140), the
overall outcomes on IQ testing at 3 yr of age between
universally screened and not screened pregnancies were
not significantly different. Importantly, assessment of
maternal thyroid function in this study and initiation of
levothyroxine when indicated occurred at 12 wk ges-
tation or thereafter.
Two studies have assessed the efficacy of targeted
screening of pregnant women for evidence of hypothy-
roidism. In the report of Vaidya et al. (133), 7.4% of
“high-risk” pregnancies were found to have TSH above
4.2 mIU/liter. This represents 1.3% of the entire popula-
tion studied. In this study, targeted screening failed to de-
tect 28% of pregnancies with elevated TSH, representing
0.7% of the total population. Li et al. (81) found in a
similar study that targeted screening missed 36% of all
individuals with a TSH above 4.0 mIU/liter.
The complexity of how to interpret and effectively
translate the above prospective investigations into clinical
screening recommendations has led to mixed viewpoints
among members of the task force. Some believe the data
support a recommendation for universal screening of
newly pregnantwomen by the ninthweek or at the time of
first visit. The Vaidya et al. (133) and Li et al. (81) studies
suggest that universal screening is easily done, is reliable,
has been deemed cost-effective in one published analysis,
is already accepted in many practices and in some coun-
tries, but also that a targeted screening approach will fail
to detect 30–40% of pregnancies with thyroid dysfunc-
tion and that targeted screening imposes the burden of an
extended questionnaire, andpossibly unreliable or incom-
plete data. The majority of committee members believed
that although secondary endpoints suggest benefit in se-
lected (TPO-Ab) populations, the primary endpoints of
both studies remain negative, and therefore a universal
mandate for all women can be recommended neither for
nor against at this time.
Regardless, there is unanimous task force agreement
that targeted screening of high-risk women is recom-
mended (Table 1) during the prenatal and perinatal peri-
ods.With this approach, the committee acknowledges the
important data confirming that such case finding will un-
fortunately miss 30% or more of women with overt or
subclinical hypothyroidism (133, 137).
Finally, women with known thyroid dysfunction and
receiving levothyroxine deserve special attention prena-
tally. T4 requirements increase 30–50%during gestation,
beginning as early as 4–6 wk gestation (141). In women
without residual thyroid function, exogenous levothyrox-
inemust be increased at the time of pregnancy detection or
hypothyroidismwill occur.Thesedata suggest that screen-
ing women with known thyroid dysfunction (receiving
levothyroxine) for abnormal TSH concentrations be-
fore pregnancy is beneficial. Furthermore, women can
be simultaneously counseled to increase their levothy-
roxine upon their first missed menstrual cycle and bio-
chemical confirmation of pregnancy. A prospective trial
confirms that a recommendation for a two-tablet-per-
week increase of their baseline levothyroxine dose (nine
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tablets per week instead of seven tablets) can substan-
tially reduce the risk of maternal hypothyroidism dur-
ing the first trimester (135).
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